mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2010-601mrj-286Research ArticleСтатьиArticlesВлияние ибандроната на риски вертебральных и невертебральных переломов при постменопаузальном остеопорозе (обзор клинических исследований)EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)ЗоткинЕ. Г.ZotkinEvgeni Germanovichezotkin@mail.ru <mailto:ezotkin@mail.ru>20102006201042№2 (2010)4246Copyright © Зоткин Е.Г., 20102010Зоткин Е.Г.Zotkin E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/286

Представлены данные большого количества клинических исследований, отвечающих принципам доказательной медицины, посвященных оценке эффективности ибандроната при постменопаузальном остеопорозе (ОП). Показано, что применение зарегистрированных форм препарата (для перорального приема 150 мг еженедельно и внутривенного введения 3 мг ежеквартально) приводит к снижению риска как вертебральных, так и невертебральных переломов, в том числе переломов проксимального отдела бедренной кости. Подчеркнуто, что одним из важных условий эффективного лечения ОП является адекватная приверженность пациентов антиостеопоротической терапии для достижения приемлемой годовой кумулятивной дозы

The paper presents data of a large number of clinical trials meeting the principles of evidence-based medicines, which have dealt with the evaluation of the efficacy of ibandronate in postmenopausal osteoporosis (OP). The administration of its registered formulations (150 mg weekly oral and 3 mg quarterly intravenous) is shown to reduce the risk of both vertebral and nonvertebral fractures, including proximal femoral fractures. It is emphasized that adequate patient adherence to antiosteopotic therapy to achieve an acceptable annual cumulative dose is one of the most important goals of effective therapy for OP

постменопаузальный остеопорозибандронатpostmenopausal osteoporosisibandronateReferences<div><p>Reginster J.Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006; 38(Suppl. 1):S4-9.</p><p>Morales-Torres J., Gutierrez-Urena S. Osteoporosis committee of Pan-American league of associations for rheumatology. The burden of osteoporosis in Latin America. Osteoporosis Int 2004; 15: 625-32.</p><p>Committee for Medicinal Products for Human Use (CHMP). Guideline on the Evaluation of new Medicinal Products in the Treatment of Primary Osteoporosis. CPMP/EWP/552/95 Rev. 2. London: European Medicines Agency, 2005.</p><p>Cranney A., Wells G., Adachi R. Non-vertebral fracture reduction with high-versus low-dose ibandronate: a meta-analysis of individual patient data. Ann Rheum Dis 2007; 66(Suppl. II): 681.</p><p>Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of nonvertebral and clinical fractures in women with post- menopausal osteoporosis: results of a metaanalysis of phase III studies. Curr Med Res Opin 2008; 24: 237-45.</p><p>Dowd R., Recker R.R., Heaney R.P. Study subjects and ordinary patients. Osteoporosis Int 2000; 11: 533-6.</p><p>Motheral B., Brooks J., Clark M.A. et al. A checklist for retrospective database studies - report of the ISPOR Task Force on Retrospective Databases. Value Health 2003; 6: 90-7.</p><p>Vray M., Hamelin B., Jaillon P. et al. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 2005; 60: 339-44.</p><p>Chesnut C.H., Ettinger M.P., Miller P.D. et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21: 391-401.</p><p>Chesnut C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.</p><p>Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-61.</p><p>Eisman J.A., Garcia-Hernandez P.A., Ortiz-Luna G. et al. Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from DIVA [abstract P316SA]. Osteoporosis Int 2006; 17:S212.</p><p>Harris S.T., Reginster J.-Y., Harley C. et al. Risk of fracture in women treated with monthly oral ibandronate or weekly 2 bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009; 44: 758-65.</p></div><br /><div><p>Reginster J.Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006; 38(Suppl. 1):S4-9.</p><p>Morales-Torres J., Gutierrez-Urena S. Osteoporosis committee of Pan-American league of associations for rheumatology. The burden of osteoporosis in Latin America. Osteoporosis Int 2004; 15: 625-32.</p><p>Committee for Medicinal Products for Human Use (CHMP). Guideline on the Evaluation of new Medicinal Products in the Treatment of Primary Osteoporosis. CPMP/EWP/552/95 Rev. 2. London: European Medicines Agency, 2005.</p><p>Cranney A., Wells G., Adachi R. Non-vertebral fracture reduction with high-versus low-dose ibandronate: a meta-analysis of individual patient data. Ann Rheum Dis 2007; 66(Suppl. II): 681.</p><p>Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of nonvertebral and clinical fractures in women with post- menopausal osteoporosis: results of a metaanalysis of phase III studies. Curr Med Res Opin 2008; 24: 237-45.</p><p>Dowd R., Recker R.R., Heaney R.P. Study subjects and ordinary patients. Osteoporosis Int 2000; 11: 533-6.</p><p>Motheral B., Brooks J., Clark M.A. et al. A checklist for retrospective database studies - report of the ISPOR Task Force on Retrospective Databases. Value Health 2003; 6: 90-7.</p><p>Vray M., Hamelin B., Jaillon P. et al. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 2005; 60: 339-44.</p><p>Chesnut C.H., Ettinger M.P., Miller P.D. et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21: 391-401.</p><p>Chesnut C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.</p><p>Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-61.</p><p>Eisman J.A., Garcia-Hernandez P.A., Ortiz-Luna G. et al. Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from DIVA [abstract P316SA]. Osteoporosis Int 2006; 17:S212.</p><p>Harris S.T., Reginster J.-Y., Harley C. et al. Risk of fracture in women treated with monthly oral ibandronate or weekly 2 bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009; 44: 758-65.</p></div><br />

The authors declare that there are no conflicts of interest present.